|Bid||187.35 x 0|
|Ask||187.36 x 0|
|Day's range||185.60 - 187.44|
|52-week range||119.01 - 191.84|
|PE ratio (TTM)||52.67|
|Forward dividend & yield||2.01 (1.27%)|
|1y target est||N/A|
NEW YORK, April 03, 2018-- Nasdaq, Inc. announced the conclusion of its Nasdaq International Designation Virtual Investor Conference on March 21, 2018. In collaboration with BNY Mellon Depositary Receipts, ...
CAMBRIDGE, Mass.--(BUSINESSWIRE)-- Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved AFLURIA QUADRIVALENT (Influenza Vaccine) for use in people five years of age and ...
RIGA, Latvia--(BUSINESSWIRE)-- Annual influenza-related hospitalizations among U.S. children younger than the age of 5 have ranged from 7,000 to 26,000 since 2010, and annual reported influenza-related ...
SUMMIT, N.J.--(BUSINESSWIRE)-- Seqirus announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2017-2018 influenza season. Seqirus, ...
HOLLY SPRINGS, N.C.--(BUSINESSWIRE)-- Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at its ...